A prospective, multicentre, open-label, randomized, phase II study of Pembrolizumab in combination with neoadjuvante (F)EC-Paclitaxel regimen in HER2-negative inflammatory breast cancer.
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Sep 2017 New trial record